The overall data highlight the relevance of therapy with new drugs in intracranial myeloma, providing a framework for future clinical trials.
2012-03-05
Eng.
Cancer
Division of Hematology, Azienda Ospedaliera Universitaria Senese, Policlinico "Santa Maria alle Scotte", Siena, Italy. gozzetti [at] unisi.it
Cancer. 2012 Mar;118(6):1574-84
© Galenicom 1999-2013